Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

publishing date : 2021 - 06 - 07    symbols : Lly    save search

DTx Pharma Appoints Jill Howe as Chief Financial Officer
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.01% H: 15.52% C: 10.16%

pharma
AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 07:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.01% H: 15.52% C: 10.16%

heart positive results trial
Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.01% H: 15.52% C: 10.16%

heart positive results trial
Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.01% H: 15.52% C: 10.16%
INCY | $52.3 -0.98% -0.99% 2.2M twitter stocktwits trandingview |
Health Technology
| | O: 0.18% H: 2.77% C: 1.95%

chinese solid tumors phase 1 results phase 3 phase 2
Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.01% H: 15.52% C: 10.16%

treatment phase 1 injection results cancer colorectal cancer phase 1b phase 2b
Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M twitter stocktwits trandingview |
Health Technology
| | O: -0.01% H: 15.52% C: 10.16%

solid tumors results trial trial results
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance

EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services

NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services

INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing

WLGS | News | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.